Introduction
============

Vulvar melanoma is the second most common vulvar cancer with an incidence of 0.1 per 100,000 individuals, presenting typically in post-menopausal women ([@b1-ijmm-33-04-0784],[@b2-ijmm-33-04-0784]). Patients with vulvar melanoma, due to the lack of body awareness, false modesty and neglect, usually present with the disease at a late stage and have a poor overall prognosis, with reported 5-year survival rates ranging from 8 to 61% ([@b3-ijmm-33-04-0784]--[@b10-ijmm-33-04-0784]). This is unlike cutaneous melanomas where, as a result of increased public and clinical awareness, many patients are now diagnosed at an early stage.

The aetiology of vulvar melanoma is poorly understood but is believed to arise *de novo*, that is, to develop from the malignant transformation of a single junctional melanocyte *in situ* ([@b4-ijmm-33-04-0784]). A genetic basis is suspected, which may explain why caucasions have a 3-fold higher incidence rate than individuals of African descent ([@b11-ijmm-33-04-0784]) and why individuals of African descent have a 2-fold shorter median survival than caucasions ([@b12-ijmm-33-04-0784]). Activating c-KIT mutations have been found in patients with vulvar melanoma ([@b13-ijmm-33-04-0784],[@b14-ijmm-33-04-0784]). By contrast, as previously demonstrated, gene mutations for cutaneous melanomas were irrelevant in vulvar melanomas (BRAF, NRAS), indicating that these two diseases have a different origin ([@b13-ijmm-33-04-0784],[@b15-ijmm-33-04-0784]).

Lichen sclerosus (LS) is also suspected to cause vulvar melanoma, and LS has indeed been reported with vulvar melanoma in 6 cases ([@b17-ijmm-33-04-0784]--[@b20-ijmm-33-04-0784]). Whereas 5 childhood vulvar melanomas cases have been reported, only 1 among thousands of adult vulvar melanoma patients have been reported ([@b18-ijmm-33-04-0784]). The mechanisms involved, however, are not clear. LS, itself an inflammatory dermatosis of unknown origin presenting with whitening of the skin and pruritus ([@b21-ijmm-33-04-0784]), is the most common precursor of HPV-negative squamous cell carcinoma of the vulva, where the postulated pathogenesis is a 'scar cancer' similar to Margolin's ulcer ([@b22-ijmm-33-04-0784],[@b23-ijmm-33-04-0784]). The difficulty of distinguishing vulvar melanoma in the setting of LS from benign pigmented lesions of the genitals is acknowledged ([@b24-ijmm-33-04-0784]).

There is no consensus regarding the adequate staging system and the treatment for vulvar melanomas. The standard FIGO staging, as used for squamous cell carcinoma, is not satisfactory. In vulvar melanomas, lesions are usually much smaller and prognosis is related to depth rather than diameter. For this reason, Breslow staging, which takes into account the depth of tumour rather than its size, seems to be most adequate and until today the best predictor of prognosis ([@b25-ijmm-33-04-0784]--[@b29-ijmm-33-04-0784]). This was also confirmed by a recent American study with 85 cases of melanomas of the female genitalia ([@b30-ijmm-33-04-0784]): a higher Breslow depth was associated with declining survival, whereas other histopathological features, such as ulcerations, increasing mitotic index and the presence of atypical melanocytic hyperplasia were not associated with a significant survival difference. Three basic histotypes (superficial spreading melanoma, mucosal lentiginous melanoma and nodular melanoma) have been described with varying incidence rates ([@b5-ijmm-33-04-0784],[@b6-ijmm-33-04-0784],[@b9-ijmm-33-04-0784],[@b31-ijmm-33-04-0784]).

It is an ongoing search for reliable histological features that allow the prognosis of vulvar melanoma; however, the majority of studies (small case series and retrospective reviews) have delivered inconclusive results. Thus, we performed a) a comprehensive literature review, b) a clinicopathological review of 33 vulvar melanoma cases of an Australian cohort to identify potential histopathological predictors of outcome, and c) immunohistochemistry for c-KIT expression in a respective tissue microarray.

Patients and methods
====================

Comprehensive literature review
-------------------------------

The systematic literature review was performed using the online websites, PubMed, Medline and Cochrane for the key words 'vulva melanoma', 'mucosal melanoma', 'melanoma', 'melanomas', 'vulvar', 'vulva' and 'vulvar neoplasm'. The retrieval was limited from 1990 to 2012 and included epidemiological studies, literature reviews, retrospective series, prospective series, meta-analyses and molecular analyses. Studies with \<10 patients were excluded, as were individual case reports. Studies were reported as to their year of publication, the number of enrolled patients, type of study, mean age of patients, 5-year overall survival, and study results and clinicopathological predictors of outcome ([Table I](#tI-ijmm-33-04-0784){ref-type="table"}).

Clinicopathological review of our study cohort
----------------------------------------------

Upon obtaining ethical approval and informed consent, we identified and enrolled 33 patients with vulvar melanoma at the Gynaecological Cancer Centre of the Royal Hospital for Women, Sydney (20 patients, incepted 1987) and the Gynaecological Cancer Centre of John Hunter Hospital, Newcastle (13 patients, incepted 1991). The following information was retrieved from the charts of the patients: age (diagnosis/menopause/relapse/death), duration of symptoms (months), menopausal status, family history of melanoma, location of melanoma, mode of detection, palpable groin nodes, lymph nodes removed/positive, CT scan results, Breslow's depth, type of surgery, chemotherapy/immunotherapy/radiotherapy (number of sessions and dose), treatment side-effects, site/location of recurrence, cause of death, and relapse-free and overall survival.

Characteristics which were assessed included diagnosis, pathogenic type (superficial spreading, mucosal lentiginous melanoma, other), predominant cell type (epithelioid, spindle or other), ulcerations, Breslow's depth, tumour infiltrating lymphocytes (TILS), regression (dermal fibrosis, lymphocytic infiltrate and, in cases of pigmented melanomas, melanophages), lymphovascular space invasion (LVSI), satellitosis (discrete tumour nests \>0.05 mm in diameter, separated from invasive tumour by ≥0.3 mm) and in-transit metastases (\>20 mm from invasive tumour), margins (involved by *in situ* or invasive melanoma), adjacent abnormal melanocytic proliferation and LS.

c-KIT immunohistochemistry of tissue microarrays
------------------------------------------------

An independent, blinded pathological review of all haematoxylin and eosin slides was performed by a pathologist specialised in vulvar pathology (Dr J.P. Scurry). These slides where marked for vulvar melanoma and two 1-mm cores were transferred onto a tissue microarray, using the ATA-100 Advancer Tissue Arrayer (Chemicon International, Temecula, CA, USA). Cores also included control tissues from negative inguinal lymph nodes that were surgically sampled. Immunohistochemistry was performed in the Bond™-X System (Leica Biosystems, Wetzlar, Germany) using the polyclonal rabbit Anti-human CD117 antibody (c-KIT; Dako, Carpinteria, CA, USA) at a 1:400 dilution followed by secondary detection with the Bond™ Polymer Refine Detection kit combining anti-mouse and anti-rabbit antibodies (Leica Biosystems). Prior to staining, antigen retrieval was performed at 95°C for 15 min in the PT Link (Dako) using the EnVision™ FLEX target retrieval solution, low pH (50×; Dako), followed by a water wash. Evaluation of the intensity of c-KIT cytoplasmic and membrane protein expression was performed by two researchers independently and consensus was reached. For the purpose of this analysis either cytoplasmic or membrane staining of 3+ intensity was taken as strong c-KIT expression.

Statistical analysis
--------------------

The clinicopathological data were collected in an in-house research database based on ACCESS (Microsoft Windows, USA) and analysed with SAS statistical software (SAS Institute Inc., Cary, NC, USA). Mean values with standard deviation and range were generated for longitudinal datasets and nominal data were presented as percentages. Potential risk factors for relapse and mortality were assessed through Kaplan-Meier curves and Cox proportional hazards models. As the number of cases was limited, the significance of each hazard ratio (HR) was primarily assessed by their effect size as p-values alone were likely to miss important results.

Results
=======

Comprehensive literature review: predictors of outcome and molecular targets for vulvar melanoma
------------------------------------------------------------------------------------------------

Our literature review revealed 46 studies with \>10 patients enrolled with vulvar melanoma ([Table I](#tI-ijmm-33-04-0784){ref-type="table"}). These studies often combined both mucosal (including those of the vulva) and cutaneous melanomas. Out of these 46 studies, 23 were retrospective studies, with 48.9% comprising the majority of publications in vulvar melanoma research, 8 studies were literature reviews, 11 comprised analyses of molecular targets, and 1 was a meta-analysis. No Cochrane review has been performed to date.

The unequivocal clinical predictors of patient outcome that were identified were inguinal lymph node status (either via sentinel or standard lymphadenectomy; 11 studies) and Breslow's depth (9 studies). Ambiguous clinical predictors included tumour ulceration (4 studies), age at diagnosis (3 studies) and DNA ploidy (3 studies).

Molecular targets suspected to be relevant in mucosal melanomas have been investigated in 11 studies. Mutations in mucosal melanomas were found in *p53* (3 studies), in *c-KIT* (2 studies) and in key kinases of the PI3K/AKT/mTOR- (1 study) and RAS/RAF/MEK/ERK-pathways (1 study). Mutations in *BRAF* or *NRAS* in mucosal melanomas were not found (1 study each) and evidence of the involvement of viral infections (HPV, HSV, polyomaviruses) in vulvar melanoma was not found either. Notably, high-throughput transcription profiling experiments on vulvar melanomas have not been performed to date.

Clinicopathological and immunological characteristics of our cohort
-------------------------------------------------------------------

The clinicopathological and immunological characteristics of the 33 patients of our cohort are summarized in [Table II](#tII-ijmm-33-04-0784){ref-type="table"}. The mean age at diagnosis was 67.5 years (range, 34--95 years) and was higher compared to that of the 47 literature review studies (62.2 years; range, 53--80 years). Patients presented with symptoms for an average of 28.2 months (range, 2--112 months) and in 72.2% of the cases detected the lesion themselves. By virtue of the advanced mean age at diagnosis almost three quarters (73.5%) of our patients were post-menopausal. The vast majority of the patients (93.8%) did not have a family history of melanoma. The most common location of vulvar melanomas was at the labia minora (31.6%) and was multifocal (26.3%).

The majority of patients presented with an advanced Breslow stage of V (56.3%) and had a mean tumour size of 21.9 mm (range, 5--50 mm), deep margin of 5.20 mm (range, 0--22 mm) and lateral margin of 3.9 mm (range, 0--12 mm). Most of our patients received radical local excision. Of the 4 patients that had received a radical vulvectomy, 3 had multifocal disease and the other was treated by an outside consultant. The majority of the patients (68.8%) underwent at least an unilateral inguino-femoral lymphadenectomy without any notable side-effects (in particular no lymphoceles or lymphoedema). For the majority of patients, this was the only adjuvant treatment received: only 25% received chemotherapy, 18.2% immunotherapy and 38.9% radiotherapy. Seventy percent of the patients relapsed, with local and distant metastases equally common: the most common local recurrence was at the vulva (30.8%). The median time to relapse was 40 months and to death 44 months. Fifty-five percent of the patients succumbed to the disease, mostly due to causes related to their disease (90%).

The majority of patients presented with a clinically or pathologically detected ulceration (53.3% or 88.9%, respectively) of a large tumour nodule of spindle cell type (52.9%), with a mean of 7.3 dermal mitoses per mm^2^ (range, 1--40) and high TILS (58.8%). The majority of the patients did not have regression (66.5%), satellitosis (88.9%), in-transit metastases (83.3%), LVSI (88.9%), or LS (88.9%). In our cohort, 3 cases of LS with vulvar melanoma were identified ([Table III](#tIII-ijmm-33-04-0784){ref-type="table"}). In all these patients, LS was observed with or without melanoma *in situ*, but always disappeared beneath the invasive melanoma. No pre-existing nevi were found, but 2 patients showed large single melanocytes at the edge of the melanoma *in situ*. Representative macroscopic images of a vulvar melanoma specimen and histological examples for various pathological features are presented in [Figs. 1](#f1-ijmm-33-04-0784){ref-type="fig"} and [2](#f2-ijmm-33-04-0784){ref-type="fig"}. An example of a strong c-KIT expression in an invasive melanoma of the vulva is illustrated in [Fig. 3](#f3-ijmm-33-04-0784){ref-type="fig"}.

Predictors of outcome for vulvar melanoma identified in our cohort
------------------------------------------------------------------

Our study confirmed the known predictive clinicopathological characteristics Breslow's depth \[relapse-free survival (RFS): HR=1.08, p=0.049\] and lymphadenectomy (RFS: HR=0.376, p=0.087, [Table IV](#tIV-ijmm-33-04-0784){ref-type="table"} and [Fig. 4A](#f4-ijmm-33-04-0784){ref-type="fig"}). These were particularly important in relation to recurrence. No significant results for positivity of lymph nodes were found in our series, possibly due to the low numbers of positive lymph nodes. In the presence of a lateral margin of \>10 mm \[disease-free survival (DFS): HR=2.7, p=0.21\] and a strong (intensity 3+) c-KIT expression (DFS: HR=1.8, p=0.49; RFS: HR=3.13, p=0.108; [Fig. 3](#f3-ijmm-33-04-0784){ref-type="fig"}), Breslow's depth becomes less important as regards the outcome ([Table IV](#tIV-ijmm-33-04-0784){ref-type="table"}, [Fig. 4B](#f4-ijmm-33-04-0784){ref-type="fig"}).

The presence of epithelioid cells within a vulvar melanoma, even when mixed in combination with spindle or nodular cells, predicted a better prognosis for these patients (HR=0.82, p=0.75) ([Table IV](#tIV-ijmm-33-04-0784){ref-type="table"}, [Fig. 5A](#f5-ijmm-33-04-0784){ref-type="fig"}). Of the 3 patients, who contribute to the plateau in the non-epithelioid curve in the Kaplan-Meier plot, 2 had a spindle/epithelioid and the other had another cell type, thus supporting our findings.

Due to our cohort size and the low numbers of certain pathological characteristics, we looked in a combined approach at high-risk pathological features, such as satellitosis, in-transit metastases, LVSI and dermal mitosis. This meant that the presence of any of these 4 features within a cancer was taken for the purpose of this analysis as the presence of a high-risk pathological feature. Using this approach, we found that in the absence of at least one of these features, none of the patients died (log-rank test, p=0.088), which had a sensitivity of 100% ([Fig. 5B](#f5-ijmm-33-04-0784){ref-type="fig"}). As regards recurrence, the presence of at least one of these pathological features increased the risk of recurrence from the disease by a factor of 5 (HR=5.02).

Independent predictors of outcome and c-KIT expression
------------------------------------------------------

We modelled the identified predictors of prognosis with each other in order to identify the degree of correlation between the predictive parameters. In all models, the strongest predictors for outcome, both in respect of relapse and survival, was the absence of any of the pathological high-risk characteristics, such as satellitosis, in-transit metastases, LVSI or dermal mitosis.

In combination with the pathological high-risk characteristics, the strongest predictors for earlier relapse were c-KIT expression \[adjusted HR (aHR)=2.51, [Table IVA](#tIV-ijmm-33-04-0784){ref-type="table"}\] and Breslow's depth (aHR=1.12, [Table IVA](#tIV-ijmm-33-04-0784){ref-type="table"}). With the increasing depth of the melanoma, lymphadenectomy presents with a HR of 6.86 (p=0.011) and Breslow's depth remains statistically significant (HR=1.13, p=0.0079). Breslow's depth, in the presence of some of the other factors, seems to be more important for recurrence than DFS. None of the classical adjuvant treatment options, including immunotherapy showed any benefit in our study.

When modelled together, the strongest predictors of earlier death were pathologically high-risk characteristics, followed by lateral margin (\>10 mm, aHR=7.32, [Table IVB](#tIV-ijmm-33-04-0784){ref-type="table"}), a strong c-KIT expression (aHR=3.34, [Table IVB](#tIV-ijmm-33-04-0784){ref-type="table"}) and lymphadenectomy (aHR=0.3, [Table IVB](#tIV-ijmm-33-04-0784){ref-type="table"}). For DFS, Breslow's depth loses its strong predictive value when compared to a lateral margin of \>10 mm and a strong c-KIT expression. The comparison of the lateral margin to strong c-KIT expression identified the lateral margin as more important for survival.

The combined multivariable model for the prediction of DFS consisted of a) lymphadenectomy, b) absence of any of the pathological high-risk characteristics, c) strong c-KIT expression, and d) Breslow's depth, and was highly statistically significant (p=0.0004).

Discussion
==========

Whilst in recent years great achievements in disease awareness, in early diagnosis, and in the treatment of cutaneous melanomas with subsequent benefits in morbidity and mortality have been made, no similar development exists for vulvar melanomas. Patients with vulvar melanomas usually present with the disease at a late stage and have a poor prognosis. Its aetiology is poorly understood and the prognostic predictors reported in the literature are not fully conclusive. Research into vulvar melanoma is also limited due to the low incidence of cases per centre and low numbers of international collaborative studies or meta-analyses.

Our comprehensive literature review of 46 studies published from 1990 until 2012 identified Breslow's depth and the inguinal lymph node status as unequivocal and tumour ulceration, age at diagnosis, and DNA ploidy as less clear or ambiguous clinical predictors of outcome. On the molecular/genetic level, mutations in *p53, c-KIT* and kinases of the PI3K/AKT/mTOR- and RAS/RAF/MEK/ERK-pathways have been reported in association with vulvar melanoma. p53 is a tumour suppressor gene ([@b65-ijmm-33-04-0784]), c-KIT is a receptor tyrosine kinase, mutations of which are integral for tumour growth and progression ([@b66-ijmm-33-04-0784]), and PI3K/AKT/mTOR- and RAS/RAF/MEK/ERK-pathways regulate growth and proliferation ([@b67-ijmm-33-04-0784],[@b68-ijmm-33-04-0784]). By contrast, neither mutations in *BRAF* or *NRAS* nor an involvement of viral infection were found. These data may not be conclusive and high-throughput transcription profiling experiments on vulvar melanomas are likely to identify additional genes, the mutations of which are associated with vulvar melanoma.

In our cohort of 33 adult patients, 3 cases (9.1%) of vulvar melanoma with LS ([Table III](#tIII-ijmm-33-04-0784){ref-type="table"}) were identified, suggesting an association. This is noteworthy, as to date, reported cases of LS associated with vulvar melanomas were mainly limited to juvenile cases ([@b16-ijmm-33-04-0784]--[@b20-ijmm-33-04-0784]) ([Table III](#tIII-ijmm-33-04-0784){ref-type="table"}). In our 3 cases, the LS was present in melanoma *in situ*, but disappeared in the invasive melanoma, where dermal hyalinisation was replaced by desmoplasia. The limited number of reports on the association of LS with adult vulvar melanoma may be due to under-reporting and lack of recognition.

In our cohort, we also found an increased c-KIT protein expression in approximately half of the patients, suggesting a role of c-KIT in vulvar melanoma. In fact, c-KIT mutations have been shown to be more common in vulvar than cutaneous melanomas ([@b13-ijmm-33-04-0784],[@b14-ijmm-33-04-0784]). c-KIT is a receptor tyrosine kinase regulating a variety of biological responses, such as chemotaxis, cell proliferation, apoptosis and adhesion in many cell types, including melanocytes, and activating KIT mutations are integral for tumour growth and progression ([@b69-ijmm-33-04-0784]); however, their role in vulvar melanoma is yet not known.

Over the years, a number of histopatological features have been shown to correlate with adverse prognosis. These include Breslow's depth, ulceration, epithelioid cell type, microsatellitosis, regression, angiolymphatic involvement, high mitotic rate, amelanosis and association with an existing nevus ([@b3-ijmm-33-04-0784],[@b5-ijmm-33-04-0784],[@b35-ijmm-33-04-0784],[@b51-ijmm-33-04-0784]). An American study demonstrated that increasing Breslow depth was associated with declining survival, whereas other histopathological features, such as ulceration, increasing mitotic index, and the presence of atypical melanocytic hyperplasia were not associated with a significant difference in survival ([@b30-ijmm-33-04-0784]). A recent Chinese study revealed that macroscopic tumour growth and treatment method were independent prognostic factors for overall survival ([@b70-ijmm-33-04-0784]). Our study confirmed Breslow's depth and lymphadenectomy as strong predictors for recurrence and poorer DFS.

Our study also identified other predictive features. Among those was the absence of any of the pathological high-risk characteristics (satellitosis, in-transit metastases, LVSI or dermal mitosis) identified in a subset of patients with vulvar melanoma. These patients survived disease with a prediction of 100% sensitivity, making the absence of these characteristics strong predictors for outcome, both in terms of relapse and survival. This group of patients may qualify for follow-up after surgery, particularly when an optimal adjuvant therapy is not available. An increased c-KIT expression was also identified as a strong negative predictor of DFS and a strong positive predictor of earlier relapse. By contrast, no significant results for positivity of lymph nodes were observed in our study, possibly due to the low numbers of positive lymph nodes.

The identification of mutated genes, such as *c-KIT* and *p53* or increased levels of c-KIT in vulvar melanomas seems consistent with the current consensus that vulvar melanomas arise *de novo* from the malignant transformation of a single junctional melanocyte *in situ* ([@b4-ijmm-33-04-0784]). Indeed, we found single large junctional melanocytes adjacent to melanoma *in situ*, which has, to our knowledge, not been reported previously. Mucosal melanomas arise from an epithelium normally devoid of melanocytes; the significance of melanocytes in a location where they are not normally present therefore requires further investigation.

The treatment of vulvar melanomas has thus far been largely restricted to surgical options, with little prospective data and no randomised studies available. Following on the trend from cutaneous melanomas, the surgical approach for vulvar melanomas has changed from extensive to more limited procedures due to the recognition that no improvement in overall survival can be achieved with aggressive surgery despite increasing patient morbidity ([@b32-ijmm-33-04-0784],[@b71-ijmm-33-04-0784]), and no benefit is found from pelvic lymphadenectomies in the absence of groin node metastases ([@b72-ijmm-33-04-0784],[@b73-ijmm-33-04-0784]), similar to squamous cell carcinomas of the vulva. In the absence of adequate randomized controlled trials, adjuvant treatments included radiotherapy, chemotherapy, immunotherapy, and in one case targeted therapy. Immunotherapy using interferon α2b has shown significantly improved DFS in randomized controlled trials, but there is significant morbidity ([@b74-ijmm-33-04-0784]--[@b76-ijmm-33-04-0784]). The role of adjuvant radiotherapy is unknown and may only be used in the case of close surgical margins, whilst recurrent cancer in the absence of metastatic disease is best managed surgically.

An important development is the evidence that mucosal (vulvar melanomas are classified as mucosal) and cutaneous melanomas are distinct genetic entities and should be studied and treated as such ([@b13-ijmm-33-04-0784],[@b15-ijmm-33-04-0784],[@b77-ijmm-33-04-0784]). Gene mutations for cutaneous melanomas did not prove to be of relevance in vulvar melanomas (BRAF, NRAS) whilst p53 and c-KIT mutations were identified and may enable therapeutic options in the future. Pathological classifiers, such as satellitosis, in-transit metastases, LVSI and dermal mitosis can stratify patients who would profit from the investigation into c-KIT expression and the subsequent imatinib treatment. Imatinib is a targeted oral therapeutic agent against cutaneous melanomas. An Australian study has shown some efficacy with the treatment of imatinib in mucosal melanomas, including vulvar melanomas ([@b78-ijmm-33-04-0784]). More studies into the genetic background, making use of high-throughput transcription profiling technology increasingly becoming available, are required to develop targeted treatment options, particularly in high-risk groups.

International trials with imatinib or any other therapeutic option available in the future in high-risk vulvar melanomas will be beneficial, but will face all the difficulties associated with targeting very rare tumours. The centralization of care for patients with vulvar melanoma is inevitable. Whilst the surgical part of their treatment is best performed in a gynaecological cancer centre, ongoing care should best be shared within a multi-disciplinary approach, involving both gynaecological oncologists and melanoma centres.

This study was supported by the Cancer Institute NSW (09/CRF/2--02 to V.H.S.); RANZCOG (to V.H-.S.); William Maxwell Trust (to V.H-.S.) and the Royal Hospital for Women Foundation (to V.H-.S.).

![(A) Spindle cell melanoma (arrow) with fibrosis adjacent to the melanoma. (B) Next to the invasive melanoma, there is melanoma *in situ* (arrow) associated with fibrosis. (C) Further away from the melanoma, there is melanoma *in situ* (arrow) and lichen sclerosus with characteristic dermal hyalinisation of lichen sclerosus.](IJMM-33-04-0784-g00){#f1-ijmm-33-04-0784}

![Scattered large atypical melanocytes without melanocytic proliferation observed at the periphery of a vulvar melanoma.](IJMM-33-04-0784-g01){#f2-ijmm-33-04-0784}

![Strong c-KIT expression in invasive melanoma of the vulva.](IJMM-33-04-0784-g02){#f3-ijmm-33-04-0784}

![Kaplan-Meier survival curves for relapse-free survival over a specific time frame (months) for patients (A) who had lymphadenectomy performed (x) versus the ones who had not (o); and (B) for patients whose tumours expressed strong c-KIT expression (o) versus those whose tumours did not (x).](IJMM-33-04-0784-g03){#f4-ijmm-33-04-0784}

![Kaplan-Meier survival curves for disease-free survival over a specific time frame (months) for patients (A) with epithelioid or mixed epithelioid tumours (o) or other histotypes (x); and (B) which expressed at least one of the following suspicious pathological features: satellitosis, in-transit metastases, lymphovascular space invasion (LVSI) or dermal mitosis (x) versus the patients which did not (o).](IJMM-33-04-0784-g04){#f5-ijmm-33-04-0784}
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Literature review.

  Author/(Refs.)                                       Year   Vulvar melanoma patients (n)   Melanoma location                  Study type                                                    Mean patient age (years)   5-year OS (%)   Results and predictors of outcome
  ---------------------------------------------------- ------ ------------------------------ ---------------------------------- ------------------------------------------------------------- -------------------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Bradgate *et al* ([@b3-ijmm-33-04-0784])             1990   50                             Vulva                              Retrospective series                                          N/A                        35              Clinical stage, patient age, ulceration, cell type, mitotic rate
  Trimble *et al* ([@b32-ijmm-33-04-0784])             1992   80                             Vulva                              Retrospective series                                          58.5                       60              Extent of vulva surgery not relevant
  Tasseron *et al* ([@b33-ijmm-33-04-0784])            1992   30                             Vulva                              Retrospective series                                          63.8                       56              Ulceration
  Piura *et al* ([@b34-ijmm-33-04-0784])               1992   18                             Vulva                              Retrospective series                                          N/A                        28.6            Positive inguinal lymph nodes not relevant
  Ragnarsson-Olding *et al* ([@b35-ijmm-33-04-0784])   1993   219                            Vulva and other mucosal melanoma   Epidemiological study                                         75                         35              Decrease in age-standardized incidence in Sweden
  Look *et al* ([@b36-ijmm-33-04-0784])                1993   16                             Vulva                              Retrospective series                                          59                         N/A             Depth \>1.75 mm predicts recurrence within 24 months
  Phillips *et al* ([@b37-ijmm-33-04-0784])            1994   71                             Vulva                              Prospective series                                            71--80                     43.9            AJCC staging, Breslow's depth
  Dunton *et al* ([@b38-ijmm-33-04-0784])              1995   N/A                            N/A                                Literature review                                             N/A                        N/A             Breslow's depth, lymph node dissection
  Scheistroen *et al* ([@b31-ijmm-33-04-0784])         1995   75                             Vulva                              Retrospective series                                          67                         46              Tumour localization clitoris, DNA ploidy, positive inguinal lymph nodes
  Raber *et al* ([@b39-ijmm-33-04-0784])               1996   89                             Vulva                              Retrospective series                                          55.4                       36.7            Breslow's depth, Clark's level, lymph node status
  Trimble ([@b40-ijmm-33-04-0784])                     1996   N/A                            N/A                                Literature review                                             N/A                        N/A             Breslow's depth
  Scheistroen *et al* ([@b41-ijmm-33-04-0784])         1996   43                             Vulva                              Retrospective series                                          64                         63              Angioinvasion, DNA ploidy
  Strauss ([@b42-ijmm-33-04-0784])                     1997   N/A                            Melanomas                          Molecular analysis                                            N/A                        N/A             p53 mutations
  Jiveskog *et al* ([@b15-ijmm-33-04-0784])            1998   N/A                            Cutaneous vs. mucosal melanomas    Molecular analysis                                            N/A                        N/A             NRAS mutations not relevant
  De Matos *et al* ([@b43-ijmm-33-04-0784])            1998   30                             Vulva                              Retrospective series                                          66                         59              Regional metastases
  Ragnarsson-Olding *et al* ([@b5-ijmm-33-04-0784])    1999   219                            Vulva                              Epidemiological study                                         N/A                        47              Breslow's depth, ulceration, amelanosis
  Larsson *et al* ([@b44-ijmm-33-04-0784])             1999   19                             Vulva                              Retrospective series                                          N/A                        23              Stage
  Creasman *et al* ([@b45-ijmm-33-04-0784])            1999   569                            Vulva                              Retrospective series                                          66                         62              AJCC stage
  Raspagliesi *et al* ([@b46-ijmm-33-04-0784])         2000   40                             Vulva                              Retrospective series                                          58                         48              Positive inguinal lymph nodes
  Verschraegen *et al* ([@b9-ijmm-33-04-0784])         2001   51                             Vulva                              Retrospective series                                          54                         27              AJCC stage, Breslow's depth
  Irvin *et al* ([@b8-ijmm-33-04-0784])                2001   14                             Vulva                              Retrospective series                                          58                         42              Margins, inguinal lymphadenectomy
  Ragnarsson-Olding *et al* ([@b47-ijmm-33-04-0784])   2002   22                             Vulva                              Molecular analysis                                                                                       p53 mutations
  De Hullu *et al* ([@b48-ijmm-33-04-0784])            2002   33                             Vulva                              Retrospective series                                          69                         52              Sentinel lymphadenectomy
  Finan and Barre ([@b49-ijmm-33-04-0784])             2003   N/A                            N/A                                Literature review                                             N/A                        N/A             Age, AJCC stage
  Ragnarsson-Olding ([@b2-ijmm-33-04-0784])            2004   1,442                          Vulva                              Meta-analysis                                                 N/A                        N/A             Breslow's depth, ulceration, amelanosis, angioinvasion, DNA ploidy
  Ragnarsson-Olding *et al* ([@b7-ijmm-33-04-0784])    2004   17                             Vulva                              Molecular analysis                                            N/A                        N/A             p53 protein levels not relevant
  Harting and Kim ([@b50-ijmm-33-04-0784])             2004   11                             Vulva                              Retrospective series                                          59                         10              Chemotherapy
  Wechter *et al* ([@b51-ijmm-33-04-0784])             2004   21                             Vulva                              Retrospective series                                          58                         N/A             Sentinel lymphadenectomy
  Edwards *et al* ([@b52-ijmm-33-04-0784])             2004   8                              Vulva                              Molecular analysis                                            N/A                        N/A             BRAF mutations not relevant
  Dahlgren *et al* ([@b53-ijmm-33-04-0784])            2005   7                              Vulva                              Molecular analysis                                            N/A                        N/A             HPV not relevant
  Stang *et al* ([@b54-ijmm-33-04-0784])               2005   102                            Vulva                              Epidemiological study                                         70                         N/A             No change in incidence rate
  Rouzier *et al* ([@b55-ijmm-33-04-0784])             2005   N/A                            N/A                                Literature review                                             N/A                        N/A             Wide local excision with tumour-free margins, sentinel lymphadenectomy
  Lundberg *et al* ([@b56-ijmm-33-04-0784])            2006   7                              Vulva                              Molecular analysis                                            N/A                        N/A             HSV not relevant
  Sugiyama *et al* ([@b10-ijmm-33-04-0784])            2007   644                            Vulva                              Retrospective series                                          68                         61              Age, stage, positive inguinal lymph nodes
  Dhar *et al* ([@b57-ijmm-33-04-0784])                2007   26                             Vulva                              Literature review                                             N/A                        N/A             Sentinel lymphadenectomy
  Giraud *et al* ([@b58-ijmm-33-04-0784])              2008   7                              Vulva                              Molecular analysis                                            N/A                        N/A             Polyomaviruses not relevant
  De Simone *et al* ([@b59-ijmm-33-04-0784])           2008   11                             Vulva                              Retrospective series                                          53                         50              N/A
  Hu *et al* ([@b11-ijmm-33-04-0784])                  2010   324                            Vulva                              Retrospective series                                          N/A                        N/A             Ethnicity
  Moan *et al* ([@b60-ijmm-33-04-0784])                2010   N/A                            Vulva                              Literature review                                             N/A                        N/A             Sun exposure not relevant
  Trifiro *et al* ([@b61-ijmm-33-04-0784])             2010   12                             Vulva                              Prospective study                                             59                         N/A             Sentinel lymphadenectomy not relevant
  Terlou *et al* ([@b62-ijmm-33-04-0784])              2010   N/A                            N/A                                Literature review                                             N/A                        N/A             ABCDE and punch biopsy are useful in diagnosis
  Baiocchi *et al* ([@b63-ijmm-33-04-0784])            2010   11                             Vulva                              Retrospective series                                          64.8                       10              Sentinel lymphadenectomy not relevant
  Ragnarsson-Olding ([@b64-ijmm-33-04-0784])           2011   N/A                            N/A                                Literature review                                             N/A                        N/A             Sun exposure not relevant
  Omholt *et al* ([@b13-ijmm-33-04-0784])              2011   23                             Vulva                              Molecular analysis                                            N/A                        N/A             KIT mutations, RAF/MEK/ERK and PI3K/AKT pathways activated
  Tcheung *et al* ([@b30-ijmm-33-04-0784])             2012   85                             Genitals/vulva                     Retrospective series                                          60.5                       50.7            N/A
  Schoenewolf *et al* ([@b14-ijmm-33-04-0784])         2012   16                             Genitals/vulva                     Retrospective series/molecular analysis                       61.9                       N/A             c-KIT expression and mutations; pERK
  Heinzelmann-Schwarz (this study)                            33                             Vulva                              Literature review, retrospective series, molecular analysis   67.5                       N/A             At least one of these pathological features: satellitosis, in-transit metastases, dermal mitosis, LVSI; strong c-KIT expression, lateral margin \>1 cm

OS, overall survival; N/A, information not available; LVSI, lymphovascular space invasion.

###### 

Clinicopathological and immunohistochemical patient characteristics.

  No.   Age   BD     ULC   DM    SAT   ITM   LVSI   LNP   IHC_C   IHC_M   Status
  ----- ----- ------ ----- ----- ----- ----- ------ ----- ------- ------- ----------
  1     51    10.5   Yes   Neg   No    No    No     0     0       0       Alive
  2     74    1.5    Yes   Neg   No    No    No     0     1.4     0.2     Alive
  3     53    1.15   No    Neg   No    No    No     N/A   N/A     N/A     Alive
  4     69    5      Yes   Neg   No    No    No     0     0       0       Alive
  5     84    3.5    Yes   Pos   Yes   No    No     0     2.2     2.75    Alive
  6     46    1      Yes   Neg   No    No    No     0     N/A     N/A     Alive
  7     62    3.1    Yes   Neg   No    No    No     0     1       1       Alive
  8     60    4      Yes   Neg   Yes   No    No     0     0.27    1.5     Deceased
  9     68    4.2    Yes   Pos   No    No    No     0     0       0       Deceased
  10    43    14     Yes   Pos   No    No    No     1     N/A     N/A     Alive
  11    96    6      Yes   Pos   No    No    No     0     2.25    1.89    Deceased
  12    91    7.5    Yes   Pos   No    No    No     0     2.11    2.11    Deceased
  13    83    0      No    N/A   No    Yes   No     0     0.5     0.75    Deceased
  14    84    N/A    N/A   N/A   N/A   N/A   N/A    3     N/A     N/A     Deceased
  15    44    6      Yes   Pos   No    No    No     N/A   0.9     0.86    Deceased
  16    71    N/A    N/A   N/A   N/A   N/A   N/A    0     N/A     N/A     Deceased
  17    68    3.3    Yes   Neg   No    No    Yes    0     1.67    2.13    Deceased
  18    76    5.2    Yes   Neg   No    Yes   No     0     0       0       Deceased
  19    50    11     Yes   N/A   No    No    No     6     1       1.18    Alive
  20    89    19.5   Yes   Pos   No    Yes   Yes    0     N/A     N/A     Alive
  21    73    1      No    Neg   No    No    No     N/A   1.5     2       Alive
  22    64    28     Yes   Pos   No    No    Yes    0     0       0       Deceased
  23    68    7      Yes   Pos   N/A   N/A   N/A    N/A   0.75    0       Deceased
  24    82    7      N/A   Pos   N/A   N/A   N/A    N/A   1       0       Deceased
  25    67    N/A    N/A   N/A   N/A   N/A   N/A    0     0       0       Deceased
  26    70    10     Yes   Pos   No    No    No     N/A   1       1.78    Alive
  27    80    3.2    Yes   Pos   No    No    No     N/A   1.75    2.38    Alive
  28    67    1      No    Neg   No    No    No     N/A   1       0.8     N/A
  29    94    1.7    Yes   Neg   No    No    No     N/A   1.83    2.17    Deceased
  30    34    N/A    N/A   N/A   N/A   N/A   N/A    N/A   1.09    1.36    Deceased
  31    81    N/A    No    N/A   N/A   N/A   N/A    0     2.08    0.89    Alive
  32    58    10     Yes   Pos   Yes   N/A   No     0     1.42    2       Alive
  33    48    2      Yes   Pos   No    N/A   No     1     1.6     2.44    Alive

No., number of patients; BD, Breslow's depth (mm); ULC, ulceration; DM, dermal mitoses \</≥5 per mm^2^; SAT, satellitosis; ITM, in-transit metastases; LVSI, lymphovascular space invasion; LNP, positive lymph nodes; IHC c-KIT expression intensity (C, cytoplasmic; M, membrane); Neg, negative; Pos, positive; N/A, information not available.

###### 

Studies identified in the literature documenting synchronous lichen sclerosus and vulvar melanoma.

  Author/(Refs.)                               Year   Age   Depth (mm)   Lymph nodes   Follow-up (months)   Status
  -------------------------------------------- ------ ----- ------------ ------------- -------------------- --------
  Friedman *et al* ([@b16-ijmm-33-04-0784])    1984   14    0.7          Negative      12                   NED
  Egan *et al* ([@b17-ijmm-33-04-0784])        1997   9     *In situ*    N/A           N/A                  N/A
  Egan *et al* ([@b17-ijmm-33-04-0784])        1997   11    0.47         N/A           N/A                  N/A
  Carlson *et al* ([@b18-ijmm-33-04-0784])     2002   83    2.7          Negative      21                   NED
  Hassanein *et al* ([@b19-ijmm-33-04-0784])   2004   10    0.44         Negative      12                   NED
  Rosamilia *et al* ([@b20-ijmm-33-04-0784])   2006   10    1            Positive      32                   NED
  De Simone *et al* ([@b59-ijmm-33-04-0784])   2008   N/A   N/A          N/A           N/A                  N/A
  This study                                          69    1            Negative      120                  DOD
  This study                                          84    3.5          Negative      12                   DOD
  This study                                          81                 Negative      2                    NED

NED, no evidence of disease; N/A, information not available; DOD, death due to disease.

###### 

Multivariable analysis of high-risk features.

  A, Relapse-free survival                                                                                          
  ------------------------------ -------------------- ------------------------------------------------------------- -------------------------------------------------------------
  Pathological characteristics   5.02 (0.62--40.61)   4.86 (0.58--40.81)                                            2.89 (0.35--23.83)
  Lymphadenectomy                0.38 (0.12--1.15)    0.15 (0.03--0.64)                                             
  Cell type                      0.75 (0.26--2.19)    0.72 (0.23--2.22)                                             
  Lateral margin                 1.95 (0.53--7.22)    1.86 (0.49--7.03)                                             
  c-KIT expression               2.45 (0.66--9.08)    3.13 (0.78--12.58)                                            2.51 (0.61--10.36)
  Breslow's depth                1.08 (1.00--1.17)                                                                  1.12 (1.02--1.22)
                                                                                                                    
  B, Disease-free survival                                                                                          
                                                                                                                    
  Predictor                      HR (95% CI)          aHR[a](#tfn4-ijmm-33-04-0784){ref-type="table-fn"} (95% CI)   aHR[b](#tfn5-ijmm-33-04-0784){ref-type="table-fn"} (95% CI)
                                                                                                                    
  Pathological characteristics                                                                                      
  Lymphadenectomy                0.71 (0.19--2.63)    0.25 (0.06--0.99)                                             0.31 (0.04--2.44)
  Cell type                      0.82 (0.25--2.73)    0.80 (0.24--2.72)                                             
  Lateral margin                 2.72 (0.58--12.88)   2.67 (0.56--12.76)                                            7.32 (0.77--69.86)
  c-KIT expression               1.82 (0.38--8.67)    1.75 (0.35--8.63)                                             3.34 (0.42--26.29)
  Breslow's depth                1.01 (0.92--1.10)    0.93 (0.57--1.50)                                             

Adjusted for Breslow's depth;

Final multivariate model.

aHR, adjusted hazard ratio; CI, confidence interval.
